Diabetic Retinopathy - Pipeline Review, H1 2014





Published: March 2014 

Description


Global Markets Direct’s, ‘Diabetic Retinopathy - Pipeline Review, H1 2014’, provides an overview of the Diabetic Retinopathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Retinopathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Retinopathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Retinopathy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diabetic Retinopathy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diabetic Retinopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Retinopathy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
 
 

Reasons to Buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Retinopathy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Retinopathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Diabetic Retinopathy Overview 8
Therapeutics Development 9
Pipeline Products for Diabetic Retinopathy - Overview 9
Pipeline Products for Diabetic Retinopathy - Comparative Analysis 10
Diabetic Retinopathy - Therapeutics under Development by Companies 11
Diabetic Retinopathy - Therapeutics under Investigation by Universities/Institutes 15
Diabetic Retinopathy - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Unknown Stage Products 19
Diabetic Retinopathy - Products under Development by Companies 20
Diabetic Retinopathy - Products under Investigation by Universities/Institutes 23
Diabetic Retinopathy - Companies Involved in Therapeutics Development 24
Antisense Therapeutics Limited 24
Lpath, Inc. 25
BioDiem Ltd 26
RegeneRx Biopharmaceuticals, Inc. 27
ThromboGenics NV 28
R-Tech Ueno, Ltd. 29
Paloma Pharmaceuticals, Inc. 30
Acucela Inc. 31
Protemix Corporation Limited 32
Gene Signal International SA 33
Promedior, Inc. 34
Inotek Pharmaceuticals Corporation 35
Intercept Pharmaceuticals, Inc. 36
FirstString Research, Inc. 37
Resolvyx Pharmaceuticals, Inc 38
Charlesson LLC. 39
Stelic Institute & Co. 40
EyeCyte, Inc. 41
Vascular Pharmaceuticals, Inc. 42
Protagonist Therapeutics Inc. 43
PanOptica, Inc. 44
EyeGene, Inc. 45
Targazyme, Inc. 46
Ampio Pharmaceuticals, Inc. 47
MingSight Pharmaceuticals 48
Bionure Farma, S.L. 49
Foresee Pharmaceuticals, LLC 50
Biomar Microbial Technologies 51
CCRP Therapeutics GmbH 52
Diabetic Retinopathy - Therapeutics Assessment 53
Assessment by Monotherapy Products 53
Assessment by Target 54
Assessment by Mechanism of Action 58
Assessment by Route of Administration 61
Assessment by Molecule Type 64
Drug Profiles 67
DMI-5207 - Drug Profile 67
LT-1009 - Drug Profile 68
ocriplasmin - Drug Profile 72
RGN-259 - Drug Profile 75
AKB-9778 - Drug Profile 77
GC-811007 - Drug Profile 79
ATL-1103 - Drug Profile 81
DG-3173 - Drug Profile 82
emixustat - Drug Profile 84
aganirsen - Drug Profile 86
GLY-230 - Drug Profile 88
EG-Mirotin - Drug Profile 90
GS-102 - Drug Profile 92
PARP Inhibitors - Drug Profile 93
DT-23552 - Drug Profile 94
RX-20001 - Drug Profile 95
P-529 - Drug Profile 96
INT-767 - Drug Profile 98
MTP-131 - Drug Profile 100
BDM-E - Drug Profile 102
RTU-007 - Drug Profile 104
A-717 - Drug Profile 105
MS-553 - Drug Profile 106
PAN-90806 - Drug Profile 107
FP-002 - Drug Profile 109
Drug For Age-Related Macular Degeneration And Diabetic Retinopathy - Drug Profile 110
Stromal Cell Therapy For Diabetic Complications - Drug Profile 111
VPI-2690-B - Drug Profile 112
Interleukin-6 Disulfide Rich Peptides Antagonist Program - Drug Profile 113
Small Molecule For Diabetic Neuropathy And Retinopathy - Drug Profile 114
ASC-101 - Drug Profile 115
V-1932 - Drug Profile 117
EC-301 Program - Drug Profile 118
C16Y Peptide - Drug Profile 119
Therapy For End-Organ Damage - Drug Profile 120
Drug to Activate EGF-Like-Domain Multiple 7 for Oncology and Diabetic Retinopathy - Drug Profile 121
Adenomatosis Polyposis Coli Down-Regulated 1 - Drug Profile 122
Autologous Stem Cell Therapy for Diabetic Retinopathy - Drug Profile 123
STNM-1510 - Drug Profile 124
CLT-010 - Drug Profile 125
IB-09A0133 - Drug Profile 126
CLT-01007 - Drug Profile 127
CLT-01001 - Drug Profile 128
CLT-01012 - Drug Profile 129
Neuregulins - Drug Profile 130
BN-201 - Drug Profile 131
EC-200 Program - Drug Profile 132
BN-204 - Drug Profile 133
BN-206 - Drug Profile 134
RGN-259 - Drug Profile 135
PRM-167 - Drug Profile 137
BN-205 - Drug Profile 139
Diabetic Retinopathy - Recent Pipeline Updates 140
Diabetic Retinopathy - Dormant Projects 166
Diabetic Retinopathy - Discontinued Products 167
Diabetic Retinopathy - Product Development Milestones 168
Featured News & Press Releases 168
Appendix 178
Methodology 178
Coverage 178
Secondary Research 178
Primary Research 178
Expert Panel Validation 178
Contact Us 179
Disclaimer 179